DWA
HAE icon

Dorsey Wright & Associates’s Haemonetics HAE Stock Holding History

Dorsey Wright & Associates’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-14,806
Closed -$1.7M – 304
2019
Q4 		$1.7M Buy
14,806
+262
+2% +$31.7K 0.56% 63
2019
Q3 		$1.83M Buy
+14,544
New +$1.85M 0.46% 91
2019
Q1 		– Sell
-43,003
Closed -$4.3M – 302
2018
Q4 		$4.3M Buy
+43,003
New +$4.52M 1.29% 19

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Dorsey Wright & Associates's HAE Position: Q1 2020 in Review

Dorsey Wright & Associates sold out of Haemonetics (HAE) in Q1 2020, closing a stake of 14,806 shares — an estimated $1.7M sold.

Dorsey Wright & Associates first reported a position in HAE in Q4 2018 and held it in 3 quarters. The position peaked at $4.3M in Q4 2018. 269 funds tracked by Wall St. Rank hold HAE as of Q1 2020.

  • Dorsey Wright & Associates reported no remaining Haemonetics position as of Q1 2020 after selling out during the quarter.
  • Dorsey Wright & Associates sold 14,806 Haemonetics shares in Q1 2020, an estimated $1.7M.
  • Dorsey Wright & Associates first reported a position in Haemonetics in Q4 2018 and held it in 3 quarters.
  • Dorsey Wright & Associates's Haemonetics position peaked at $4.3M in Q4 2018.
  • 269 funds tracked by Wall St. Rank held Haemonetics as of Q1 2020.

Based on Dorsey Wright & Associates's 13F filing for Q1 2020, filed 20 Apr 2020.